Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
Identifieur interne : 002344 ( PubMed/Corpus ); précédent : 002343; suivant : 002345Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
Auteurs : Raymond H. See ; Alexander N. Zakhartchouk ; Martin Petric ; David J. Lawrence ; Catherine P Y. Mok ; Robert J. Hogan ; Thomas Rowe ; Lois A. Zitzow ; Karuna P. Karunakaran ; Mary M. Hitt ; Frank L. Graham ; Ludvik Prevec ; James B. Mahony ; Chetna Sharon ; Thierry C. Auperin ; James M. Rini ; Aubrey J. Tingle ; David W. Scheifele ; Danuta M. Skowronski ; David M. Patrick ; Thomas G. Voss ; Lorne A. Babiuk ; Jack Gauldie ; Rachel L. Roper ; Robert C. Brunham ; B Brett FinlaySource :
- The Journal of general virology [ 0022-1317 ] ; 2006.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Antibody Specificity, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Immunoglobulin A (blood), Immunoglobulin A (immunology), Injections, Intramuscular, Injections, Subcutaneous, Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Neutralization Tests, Nucleocapsid Proteins (genetics), SARS Virus (chemistry), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccination, Vaccines, DNA (administration & dosage), Vaccines, DNA (genetics), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage).
- MESH :
- chemical , administration & dosage : Vaccines, DNA, Viral Vaccines.
- chemical , blood : Antibodies, Viral, Immunoglobulin A.
- chemical , genetics : Membrane Glycoproteins, Nucleocapsid Proteins, Vaccines, DNA, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Viral, Immunoglobulin A, Membrane Glycoproteins, Viral Envelope Proteins.
- chemistry : SARS Virus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Intranasal, Animals, Antibody Specificity, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Injections, Intramuscular, Injections, Subcutaneous, Mice, Neutralization Tests, Spike Glycoprotein, Coronavirus, Vaccination.
Abstract
Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.
DOI: 10.1099/vir.0.81579-0
PubMed: 16476986
Links to Exploration step
pubmed:16476986Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.</title><author><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H" last="See">Raymond H. See</name><affiliation><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Zakhartchouk, Alexander N" sort="Zakhartchouk, Alexander N" uniqKey="Zakhartchouk A" first="Alexander N" last="Zakhartchouk">Alexander N. Zakhartchouk</name></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name></author><author><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J" last="Lawrence">David J. Lawrence</name></author><author><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P Y" last="Mok">Catherine P Y. Mok</name></author><author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J" last="Hogan">Robert J. Hogan</name></author><author><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name></author><author><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A" last="Zitzow">Lois A. Zitzow</name></author><author><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P" last="Karunakaran">Karuna P. Karunakaran</name></author><author><name sortKey="Hitt, Mary M" sort="Hitt, Mary M" uniqKey="Hitt M" first="Mary M" last="Hitt">Mary M. Hitt</name></author><author><name sortKey="Graham, Frank L" sort="Graham, Frank L" uniqKey="Graham F" first="Frank L" last="Graham">Frank L. Graham</name></author><author><name sortKey="Prevec, Ludvik" sort="Prevec, Ludvik" uniqKey="Prevec L" first="Ludvik" last="Prevec">Ludvik Prevec</name></author><author><name sortKey="Mahony, James B" sort="Mahony, James B" uniqKey="Mahony J" first="James B" last="Mahony">James B. Mahony</name></author><author><name sortKey="Sharon, Chetna" sort="Sharon, Chetna" uniqKey="Sharon C" first="Chetna" last="Sharon">Chetna Sharon</name></author><author><name sortKey="Auperin, Thierry C" sort="Auperin, Thierry C" uniqKey="Auperin T" first="Thierry C" last="Auperin">Thierry C. Auperin</name></author><author><name sortKey="Rini, James M" sort="Rini, James M" uniqKey="Rini J" first="James M" last="Rini">James M. Rini</name></author><author><name sortKey="Tingle, Aubrey J" sort="Tingle, Aubrey J" uniqKey="Tingle A" first="Aubrey J" last="Tingle">Aubrey J. Tingle</name></author><author><name sortKey="Scheifele, David W" sort="Scheifele, David W" uniqKey="Scheifele D" first="David W" last="Scheifele">David W. Scheifele</name></author><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name></author><author><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M" last="Patrick">David M. Patrick</name></author><author><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G" last="Voss">Thomas G. Voss</name></author><author><name sortKey="Babiuk, Lorne A" sort="Babiuk, Lorne A" uniqKey="Babiuk L" first="Lorne A" last="Babiuk">Lorne A. Babiuk</name></author><author><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name></author><author><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L" last="Roper">Rachel L. Roper</name></author><author><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C" last="Brunham">Robert C. Brunham</name></author><author><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B Brett" last="Finlay">B Brett Finlay</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16476986</idno><idno type="pmid">16476986</idno><idno type="doi">10.1099/vir.0.81579-0</idno><idno type="wicri:Area/PubMed/Corpus">002344</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002344</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.</title><author><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H" last="See">Raymond H. See</name><affiliation><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Zakhartchouk, Alexander N" sort="Zakhartchouk, Alexander N" uniqKey="Zakhartchouk A" first="Alexander N" last="Zakhartchouk">Alexander N. Zakhartchouk</name></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name></author><author><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J" last="Lawrence">David J. Lawrence</name></author><author><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P Y" last="Mok">Catherine P Y. Mok</name></author><author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J" last="Hogan">Robert J. Hogan</name></author><author><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name></author><author><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A" last="Zitzow">Lois A. Zitzow</name></author><author><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P" last="Karunakaran">Karuna P. Karunakaran</name></author><author><name sortKey="Hitt, Mary M" sort="Hitt, Mary M" uniqKey="Hitt M" first="Mary M" last="Hitt">Mary M. Hitt</name></author><author><name sortKey="Graham, Frank L" sort="Graham, Frank L" uniqKey="Graham F" first="Frank L" last="Graham">Frank L. Graham</name></author><author><name sortKey="Prevec, Ludvik" sort="Prevec, Ludvik" uniqKey="Prevec L" first="Ludvik" last="Prevec">Ludvik Prevec</name></author><author><name sortKey="Mahony, James B" sort="Mahony, James B" uniqKey="Mahony J" first="James B" last="Mahony">James B. Mahony</name></author><author><name sortKey="Sharon, Chetna" sort="Sharon, Chetna" uniqKey="Sharon C" first="Chetna" last="Sharon">Chetna Sharon</name></author><author><name sortKey="Auperin, Thierry C" sort="Auperin, Thierry C" uniqKey="Auperin T" first="Thierry C" last="Auperin">Thierry C. Auperin</name></author><author><name sortKey="Rini, James M" sort="Rini, James M" uniqKey="Rini J" first="James M" last="Rini">James M. Rini</name></author><author><name sortKey="Tingle, Aubrey J" sort="Tingle, Aubrey J" uniqKey="Tingle A" first="Aubrey J" last="Tingle">Aubrey J. Tingle</name></author><author><name sortKey="Scheifele, David W" sort="Scheifele, David W" uniqKey="Scheifele D" first="David W" last="Scheifele">David W. Scheifele</name></author><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name></author><author><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M" last="Patrick">David M. Patrick</name></author><author><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G" last="Voss">Thomas G. Voss</name></author><author><name sortKey="Babiuk, Lorne A" sort="Babiuk, Lorne A" uniqKey="Babiuk L" first="Lorne A" last="Babiuk">Lorne A. Babiuk</name></author><author><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name></author><author><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L" last="Roper">Rachel L. Roper</name></author><author><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C" last="Brunham">Robert C. Brunham</name></author><author><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B Brett" last="Finlay">B Brett Finlay</name></author></analytic><series><title level="j">The Journal of general virology</title><idno type="ISSN">0022-1317</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (immunology)</term><term>Antibody Specificity</term><term>Disease Models, Animal</term><term>Drug Evaluation, Preclinical</term><term>Female</term><term>Immunoglobulin A (blood)</term><term>Immunoglobulin A (immunology)</term><term>Injections, Intramuscular</term><term>Injections, Subcutaneous</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Neutralization Tests</term><term>Nucleocapsid Proteins (genetics)</term><term>SARS Virus (chemistry)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccination</term><term>Vaccines, DNA (administration & dosage)</term><term>Vaccines, DNA (genetics)</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term><term>Nucleocapsid Proteins</term><term>Vaccines, DNA</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin A</term><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Antibody Specificity</term><term>Disease Models, Animal</term><term>Drug Evaluation, Preclinical</term><term>Female</term><term>Injections, Intramuscular</term><term>Injections, Subcutaneous</term><term>Mice</term><term>Neutralization Tests</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16476986</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1317</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>Pt 3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of general virology</Title><ISOAbbreviation>J. Gen. Virol.</ISOAbbreviation></Journal><ArticleTitle>Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.</ArticleTitle><Pagination><MedlinePgn>641-50</MedlinePgn></Pagination><Abstract><AbstractText>Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>See</LastName><ForeName>Raymond H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakhartchouk</LastName><ForeName>Alexander N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Petric</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Catherine P Y</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Hogan</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zitzow</LastName><ForeName>Lois A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Karunakaran</LastName><ForeName>Karuna P</ForeName><Initials>KP</Initials></Author><Author ValidYN="Y"><LastName>Hitt</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Frank L</ForeName><Initials>FL</Initials></Author><Author ValidYN="Y"><LastName>Prevec</LastName><ForeName>Ludvik</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mahony</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Sharon</LastName><ForeName>Chetna</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Auperin</LastName><ForeName>Thierry C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Rini</LastName><ForeName>James M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Tingle</LastName><ForeName>Aubrey J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Scheifele</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Skowronski</LastName><ForeName>Danuta M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Patrick</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Babiuk</LastName><ForeName>Lorne A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Gauldie</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Roper</LastName><ForeName>Rachel L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Brunham</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Finlay</LastName><ForeName>B Brett</ForeName><Initials>BB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Gen Virol</MedlineTA><NlmUniqueID>0077340</NlmUniqueID><ISSNLinking>0022-1317</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16476986</ArticleId><ArticleId IdType="pii">87/3/641</ArticleId><ArticleId IdType="doi">10.1099/vir.0.81579-0</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002344 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002344 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16476986
|texte= Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16476986" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |